OR WAIT null SECS
Dupilumab became the first approved treatment for eosinophilic esophagitis in 2022.
Dupilumab (Dupixent) results in a reduction in dysphagia, 1 of the most prominent symptoms of patients with eosinophilic esophagitis (EoE).
In the year since the drug became the first treatment approved by the US Food and Drug Administration (FDA) for EoE, there have been a number of improvements seen in controlling the symptoms of the disease.
In an abstract presented during the 2023 Digestive Disease Week (DDW) in Chicago, Evan S. Dellon, MD, MPH, FACG, Professor of Medicine and Adjunct Professor of Epidemiology, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, discussed the ongoing positive data for dupilumab in treating patients with EoE, including some positive data on a reduction in dysphagia.
Dellon discussed the new data in an interview with HCPLive®, which showed a marked improvement in both the mean days with any action taken for dysphagia relief and the number of days with more severe dysphagia, indicated by the need to cough/gag, vomit, or seek medical attention to relieve dysphagia at week 24 compared to placebo.
The data was part of the ongoing phase 3 LIBERTY-EoE-TREET trial evaluating dupilumab in patients with EoE.